Experimental Research of Sintered Porous Materials of Bronze Powders

Porous sample were fabricated by sintering of bronze ( Cu Sn10) with different particle size range. The paper investigates the influence of the particle size distribution, temperature and sintering time on the structural characteristics (porosity, pore size, dimensional changes) of the porous parts studied. A porous structure with small-sized pores and a uniform distribution of the pore sizes is obtained in conditions of a narrow range of particle size distribution, small size of the powder particles and optimal sintering parameters

Comparative Study Between Solid State Welding and Radiant Energy Welding Processes for Joining Metallic Glassy Ribbons

Amorphous alloys have emerged as an important class of advanced materials that own a combination of properties, such as mechanical strength, hardness, high elasticity modulus and a very good corrosion resistance. Since the number of amorphous structures alloys increased in the last decades, ways of joining such materials were studied in order to produce complex structures or increase their size. Thus, if this kind of complex products are obtained, it will diversify their applicability in multiple and various domains. For this research two ways of joining amorphous ribbons has been studied: solid state welding and radiant energy welding. For the radiant energy welding process, it was selected electron beam welding (EBW) method and for the solid-state welding process, ultrasonic welding (UW) method was chosen. Seeing that these methods have found applicability in industries, a comparative study was done in order to see which one offers the best outcome. Recently, in the last years, such products were embedded in a polymer matrix, creating thus, composite materials that have improved mechanical properties. This raised curiosity for major industries, such as aero-space, medical and automotive. Amorphous ribbons from Ni-Fe-Cr-Si-B and Al-Ni-Nd-Co alloy families were welded by EBW method, and Cu-Zr-Al amorphous ribbons were welded by the UW method. Microstructure characterization has been performed by SEM, EDX, XRD and DSC analyses

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

Background Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. Methods Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. Results A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55). Conclusions Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218. opens in new tab.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Critical Europeans in an Age of Crisis: Irish and Portuguese Protesters’ EU Perceptions*

Moore M, Trommer S. Critical Europeans in an age of Crisis: Irish and Portuguese Protesters' EU Perceptions. Journal of Common Market Studies. 2021;59(2):316-334.This article examines Irish and Portuguese protesters' perceptions of the EU in the decade since the European debt crisis. Building on EU politics, social movement and protest literatures, we ask how domestic protesters in both countries perceive the EU during its age of crisis protest timescape. We find that critical Europeanism, which rejects technocratic and neoliberal Europe and works towards an alternative, social Europe, has travelled beyond austerity/bailout protests into women's rights and housing protests in both countries, although to varying degrees. We suggest that the expansion of critical European perceptions in these traditionally Europhile member states forms part of the social and political legacy of the European debt crisis, but also contributes to the continued Europeanization of the European social movement space. It could have positive impacts on the EU's legitimacy deficit if EU institutions engaged meaningfully with critical European voices